<unk>  is used for the treatment of adults with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
Tivozanib
Vatalanib
Pegaptanib
Pazopanib
Nintedanib
Abrocitinib
Gilteritinib
Erdafitinib